Compare · BSX vs DRTS
BSX vs DRTS
Side-by-side comparison of Boston Scientific Corporation (BSX) and Alpha Tau Medical Ltd. (DRTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and DRTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $62.32B, about 49.9x DRTS ($1.25B).
- Over the past year, BSX is down 54.9% and DRTS is up 211.3% - DRTS leads by 266.1 points.
- BSX has been more active in the news (5 items in the past 4 weeks vs 1 for DRTS).
- BSX has more recent analyst coverage (25 ratings vs 7 for DRTS).
- Company
- Boston Scientific Corporation
- Alpha Tau Medical Ltd.
- Price
- $44.11-0.11%
- $12.17-7.59%
- Market cap
- $62.32B
- $1.25B
- 1M return
- +1.30%
- -21.38%
- 1Y return
- -54.87%
- +211.25%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 7
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest DRTS
- Alpha Tau to Participate in October Investor Conferences
- Alpha Tau to Participate in September Investor Conferences
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
- Chief Financial Officer Levy Raphi exercised 2,871 units of Ordinary Shares at a strike of $2.98 and sold $43,073 worth of Ordinary Shares (2,871 units at $15.00) (SEC Form 4)
- Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
- Chief Financial Officer Levy Raphi exercised 17,730 units of Ordinary Shares at a strike of $2.98 and sold $248,277 worth of Ordinary Shares (17,730 units at $14.00) (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 6-K filed by Alpha Tau Medical Ltd.